Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Immucell (ICCC) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Immucell (ICCC) over the last 16 years, with Q3 2025 value amounting to 0.36%.

  • Immucell's EBITDA Margin rose 99300.0% to 0.36% in Q3 2025 from the same period last year, while for Sep 2025 it was 8.39%, marking a year-over-year increase of 201200.0%. This contributed to the annual value of 6.19% for FY2024, which is 267100.0% up from last year.
  • As of Q3 2025, Immucell's EBITDA Margin stood at 0.36%, which was up 99300.0% from 8.84% recorded in Q2 2025.
  • Over the past 5 years, Immucell's EBITDA Margin peaked at 13.85% during Q1 2025, and registered a low of 65.46% during Q1 2023.
  • Moreover, its 5-year median value for EBITDA Margin was 6.63% (2021), whereas its average is 10.42%.
  • As far as peak fluctuations go, Immucell's EBITDA Margin tumbled by -749700bps in 2023, and later surged by 613200bps in 2024.
  • Quarter analysis of 5 years shows Immucell's EBITDA Margin stood at 2.67% in 2021, then tumbled by -1664bps to 41.77% in 2022, then skyrocketed by 47bps to 21.94% in 2023, then soared by 137bps to 8.02% in 2024, then crashed by -95bps to 0.36% in 2025.
  • Its last three reported values are 0.36% in Q3 2025, 8.84% for Q2 2025, and 13.85% during Q1 2025.